Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression

Figure 2

Expression levels of miR-34a, miR-150, and miR-923 in cancerous and non-malignant sample groups in the validation cohort and independent data set. (A) Cancer samples show significantly higher miR-34a expression (p-value < 0.001) compared to non-malignant samples in both the validation plasma samples and independent tumour tissue samples. (B) Cancer samples show significantly lower miR-150 expression compared to non-malignant samples in both the validation plasma samples (p-value =0.003) and independent tumour tissue samples (p-value < 0.001). (C) No significant change in miR-923 expression is observed in either the validation plasma samples (p-value = 0.56) or the independent tumour tissue samples (p-value = 0.35). The non-malignant group in the validation cohort represents the normal, polyp, and adenoma samples. Cancer groups in both studies represent cancers of all stages I-IV. Expression levels of the miRNAs (log10 scale at y-axis) are normalised to let-7e in the validation cohort and mean normalised in the independent dataset. Statistically significant differences between groups were determined using Wilcoxon rank sum tests in both the validation and independent cohorts.

Back to article page